PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Access to clinical trials drives dramatic increases in survival from childhood cancer

2012-07-18
(Press-News.org) More children are surviving cancer in Britain than ever before according to new research published in the cancer journal Annals of Oncology [1] today (Wednesday). The improvement in survival has been driven by the increasing numbers taking part in clinical trials since 1977 when the UK Children's Cancer Study Group (UKCCSG) [2] was established.

The UKCCSG's principal aim was to set up a comprehensive portfolio of national and international trials for the majority of children's cancers. As result, between 1978 and 2005 two-thirds of children diagnosed with cancer in Britain had a cancer type for which there was an open national or international clinical trial. During this time, survival for the whole population of affected children increased significantly in all these categories, with the greatest improvements being seen in germ cell tumours (tumours in the testes and ovaries), and hepatoblastoma (a rare liver tumour). Only 28% of children diagnosed with cancer between 1966-1970 survived for five years. By 2005 this had increased dramatically to 79%

Charles Stiller, Registry Director at the Childhood Cancer Research Group, University of Oxford (UK) and first author of the study, said: "The results of our study show that improvements in childhood cancer survival match those reported by the relevant clinical trials that were running between 1978 and 2005. During this time there has been an increasing level of participation in trials, with around 90% of all children with many types of cancer enrolled, and this has been facilitated by the organisation of care into specialist children's cancer units. These developments have underpinned the substantial improvements in survival seen at the population level – in other words, among a large, unselected group of all children with cancer in Britain.

"Although trends in childhood cancer survival have been reported in relation to improvements in treatment in the UK and elsewhere, this is the first time that population-based survival has been examined in relation to the clinical trials open to entry at the time."

Mr Stiller and his colleagues analysed data on 25,853 children (66% of all registered childhood cancers) diagnosed before the age of 15 in Britain during 1978-2005. In total there were 39,067 children with cancer, but this study focused on the two-thirds for whom there was a multi-centre trial of first-line treatment open to entry during a total of at least 10 years within the period of the study.

For each diagnostic category, there was an annual reduction in the risk of death that ranged from 2.7% for rhabdomyosarcoma (a cancer of soft tissues such as muscle) to 12% for germ cell tumours of the testes and ovaries. The percentage of children enrolled in trials varied widely between different cancers and at different times during the study period, but there was a tendency for entry rates to be higher in more recent times for most cancers.

"Examples of cancers where a really big difference was seen over the study period are acute lymphoblastic leukaemia (ALL) and hepatoblastoma," said Mr Stiller. "ALL is the most frequent cancer in children. In 1978 only 49% of children survived for five years, but survival increased steadily throughout the study period and from each trial era to the next. By the end of this study, 90% of children were surviving five years from diagnosis and most of them could be considered cured.

"Hepatoblastoma is one of the rarer childhood cancers, with less than 20 cases per year in the UK – far too few for any one country to run a clinical trial on its own. In the years before the first worldwide trial for treatment of the disease, two-thirds of children with this tumour died, whereas now three-quarters survive. This illustrates what can be achieved with strong commitment to international collaboration, even for comparatively rare tumours."

Kathy Pritchard-Jones, Professor of Paediatric Oncology at the Institute of Child Health, University College London and Great Ormond Street Hospital for Children NHS Trust (London, UK), another author of the study, said: "The key message from this study is that clinical trials are good for you if you are a cancer patient. Taking part in clinical trials is considered best practice for most newly diagnosed childhood cancers now. This study shows how the increase in the proportion of children taking part in trials has gone hand in hand with improvements in survival. It also emphasises the importance of doctors working together to take the leadership role to make sure clinical trials and access to new treatments are available for children with cancer. Despite initiatives at a European level to incentivise the pharmaceutical industry, they still have a very poor track record in initiating or supporting clinical trials that could benefit children with cancer.

"The study also shows the importance of knowing how many children have cancer each year in the country, having detailed clinical information on the cancer type, including how many patients take part in a clinical trial, and being able to link this to survival for the whole population of children with cancer. Only in this way is it possible to track the impact of clinical trial availability and participation over time on survival from cancer."

The authors say they found no evidence that the absence of a trial resulted in a worsening of survival for children with those cancers, but the periods without an open trial between 1978-2005 were short, resulting in too few patients for formal comparisons. "Since the implementation of the EU Clinical Trials Directive in 2004, comprehensive trial portfolios are no longer available and intervals between trials have increased. As data for recent years mature, it will be important to investigate the effects on survival from childhood cancer at the population level in relation to trial entry, to address the important question of whether patients who participate in clinical trials have better outcomes than those who do not," conclude the authors in their paper. The Childhood Cancer Research Group will continue to monitor survival at population level.

Prof Pritchard-Jones said: "If no trial is available it may not have an immediate effect on survival. However, if that situation were to persist for many years, one would predict that the rate of improvement of survival would cease and children in the UK would no longer be receiving 'cutting edge' treatment at the international forefront of innovative thinking. There is still a great need for this in many, if not all childhood cancers, due to the toxicity of the treatment, its propensity to cause side effects later in life, and the fact that we still don't cure everyone."

###

Notes:
[1] "Population survival from childhood cancer in Britain during 1978-2005 by eras of entry to clinical trials", by CA Stiller, ME Kroll, K Pritchard-Jones. Annals of Oncology. doi:10.1093/annonc/mds183
[2] In 2006 the UKCCSG was succeeded by the Children's Cancer and Leukaemia Group.

END



ELSE PRESS RELEASES FROM THIS DATE:

20-year quest ends as scientists pin down structure of elusive, heart-protective protein

2012-07-18
It is a cellular component so scarce, some scientists even doubted its existence, and many others gave up searching for its molecular structure. Now a team led by researchers at Johns Hopkins has defined the protein structural composition of mitoKATP, a potassium channel in the mitochondria of the heart and other organs that is known to protect against tissue damage due to a heart attack or stroke. Importantly, the newly found channel strongly improves heart cell survival, demonstrating an essential life-saving role. In a report to be published in the journal Circulation ...

Johns Hopkins researchers link 2 biological risk factors for schizophrenia

2012-07-18
Johns Hopkins researchers say they have discovered a cause-and-effect relationship between two well-established biological risk factors for schizophrenia previously believed to be independent of one another. The findings could eventually lead researchers to develop better drugs to treat the cognitive dysfunction associated with schizophrenia and possibly other mental illnesses. Researchers have long studied the role played in the brain's neurons by the Disrupted-in-Schizophrenia 1 (DISC1) gene, a mutation with one of the strongest links to an increased risk of developing ...

Study may explain how exercise improves heart function in diabetics

2012-07-18
A detailed study of heart muscle function in mice has uncovered evidence to explain why exercise is beneficial for heart function in type 2 diabetes. The research team, led by scientists at the Johns Hopkins University School of Medicine, found that greater amounts of fatty acids used by the heart during stressful conditions like exercise can counteract the detrimental effects of excess glucose and improve the diabetic heart's pumping ability in several ways. The findings also shed light on the complex chain of events that lead to diabetic cardiomyopathy, a form of heart ...

BGI debuts new tool 'PDXomics' for tumor xenograft research and applications

2012-07-18
July 17, 2012, Shenzhen, China – BGI, the world's largest genomics organization, announced today that it has successfully developed a new filtering tool, PDXomics, which performs accurate and specific classification of the mixed reads derived from the host and tumor xenografts. Through the full utilization of this robust tool, researchers could develop the specific patient-derived xenografts (PDX) and advance the oncology drug discovery, biomarker development and their future applications. Xenograft models serve as an important tool for many areas of biomedical research, ...

Beating the fuel prices: Using yeast for economic production of bioethanol

2012-07-18
Finding renewable and economic sources of energy are one of the most important concerns for the continuation of the human species. New research, published in BioMed Central's open access journal Biotechnology for Biofuels, has produced a novel strain of yeast with improved xylose tolerance and metabolism, and consequently improved ethanol production. Bioethanol is considered one of cleanest renewable replacements for fossil fuel. However using glucose from crops, such as sugar cane or starch crops, uses up resources which could otherwise be used to produce food. Xylose ...

Milk thistle, taken by many people for liver disease, ineffective as treatment for hepatitis C

2012-07-18
CHAPEL HILL, N.C. – Silymarin or "milk thistle," a popular herbal dietary supplement that many people take for liver ailments, works no better than placebo in patients with chronic hepatitis C infection. That's the conclusion of a multicenter clinical trial published in the July 18, 2012 issue of the Journal of the American Medical Association. "Patients ask me about milk thistle all the time," said Michael W. Fried, MD, lead author of the study, a professor in the University of North Carolina School of Medicine and director of the UNC Liver Center. "Now I can tell ...

Certain jobs dads do linked to higher risk of birth defects

2012-07-18
Several types of job carried out by future fathers may be linked to an increased risk of birth defects in their babies, suggests research published online in Occupational and Environmental Medicine. Previous research has linked certain occupations with a higher risk of birth defects in offspring. But it has tended to lump together very different types of defects and occupations, in order to achieve large sample sizes, with the attendant potential to skew the results, say the authors. They base their findings on data from the ongoing US National Birth Defects Prevention ...

Workplace exposure to organic solvents linked to heart defects at birth

2012-07-18
Workplace exposure to organic solvents is linked to several types of heart defects at birth, indicates research published online in Occupational and Environmental Medicine. Organic solvents are widely used for dissolving or dispersing substances, such as fats, oils, and waxes, as well as in chemical manufacturing. They are found in paints, varnishes, adhesives, degreasing/cleaning agents, dyes, polymers, plastic, synthetic textiles, printing inks and agricultural products. Most organic solvents are highly volatile and enter the body through the lungs, but can also ...

Vitamin B12 supplements may help treat hepatitis C

2012-07-18
Adding vitamin B12 to standard hepatitis C virus (HCV) treatment significantly boosts the body's ability to keep the virus at bay, indicates a pilot study published online in the journal Gut. The effects were particularly strong in patients whose infection was proving difficult to treat effectively, the findings showed. Between 60% and 80% of those infected with the viral liver infection HCV will go on to develop chronic hepatitis, and roughly a third of them will progress to cirrhosis and terminal liver disease. Standard treatment of interferon (peg IFN) and ribavarin ...

Man-made pores mimic important features of natural pores

2012-07-18
BUFFALO, N.Y. -- Inspired by nature, an international research team has created synthetic pores that mimic the activity of cellular ion channels, which play a vital role in human health by severely restricting the types of materials allowed to enter cells. The pores the scientists built are permeable to potassium ions and water, but not to other ions such as sodium and lithium ions. This kind of extreme selectivity, while prominent in nature, is unprecedented for a synthetic structure, said University at Buffalo chemistry professor Bing Gong, PhD, who led the study. The ...

LAST 30 PRESS RELEASES:

New study finds mechanical valves offer superior long-term survival for aortic valve replacement patients aged 60 and younger

Anatomic lung resection linked to improved survival for early-stage lung cancer

Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer

Blood test could guide use of anti-inflammatory drug celecoxib to reduce risk of colon cancer recurrence

Blood test from Alliance trial guides use of anti-inflammatory drug to lower colon cancer recurrence risk

New dyes pave way for better photothermal cancer treatment and diagnosis

New drug shows promise in restoring vision for people with nerve damage

Scientists discover unique microbes in Amazonian peatlands that could influence climate change

University Hospitals now offering ultra-minimally invasive endoscopic spine surgery for patients experiencing back pain

JNM publishes procedure standard/practice guideline for fibroblast activation protein PET

What to do with aging solar panels?

Scientists design peptides to enhance drug efficacy

Collaboration to develop sorghum hybrids to reduce synthetic fertilizer use and farmer costs

Light-activated ink developed to remotely control cardiac tissue to repair the heart

EMBARGOED: Dana-Farber investigators pinpoint keys to cell therapy response for leukemia

Surgeon preference factors into survival outcomes analyses for multi- and single-arterial bypass grafting

Study points to South America – not Mexico – as birthplace of Irish potato famine pathogen

VR subway experiment highlights role of sound in disrupting balance for people with inner ear disorder

Evolution without sex: How mites have survived for millions of years

U. of I. team develops weight loss app that tracks fiber, protein content in meals

Progress and challenges in brain implants

City-level sugar-sweetened beverage taxes and changes in adult BMI

Duration in immigration detention and health harms

COVID-19 pandemic and racial and ethnic disparities in long-term nursing home stay or death following hospital discharge

Specific types of liver immune cells are required to deal with injury

How human activity has shaped Brazil Nut forests’ past and future

Doctors test a new way to help people quit fentanyl 

Long read sequencing reveals more genetic information while cutting time and cost of rare disease diagnoses

AAAS and ASU launch mission-driven collaborative to strengthen scientific enterprise

Medicaid-insured heart transplant patients face higher risk of post-transplant complications

[Press-News.org] Access to clinical trials drives dramatic increases in survival from childhood cancer